About
Tilray Brands (NASDAQ:TLRY) shares rose 2.3% to $7.22, with trading volume up 77% from the average. Analysts have mixed ratings: ATB Cap Markets downgraded to "strong sell," Jefferies raised the target to $20 with a "buy" rating, and Wall Street Zen upgraded to "hold." The stock has a "Hold" consensus with a $20 target price. Institutional investors have increased their stakes. Tilray engages in medical cannabis distribution globally.
Tilray Brands Inc. (TLRY) shares rose 2.27% to $7.22 on Thursday, outperforming the NASDAQ Composite Index, which rose 0.22%, and the Dow Jones Industrial Average, which fell 0.07%. This rise ended a four-day losing streak. The stock is 68.88% below its 52-week high of $23.20. Trading volume was 8.9 million, above the 50-day average of 7.8 million.
It may be time for investors to cut their losses.
09:39 AM EST - Tilray Brands, Inc. : Today released its 2025 Cannabis Holiday Gift Guide, showcasing Canadians’ top picks for gifting, entertaining, and seasonal celebrations. Tilray Brands, Inc. shares T.TLRY are trading unchanged at $9.86.
Robert Moskow from TD Cowen maintains a Buy rating on Tilray, adjusting the price target to $10 due to a reverse stock split. The valuation considers a lower enterprise value to EBITDA multiple of 12x, reflecting market challenges in craft beer and Canadian sectors. Despite these challenges, Moskow remains cautiously optimistic about Tilray's financial performance.
